title: Intravenous lorazepam as an amnestic and anxiolytic agent in the intensive care unit: a prospective study.
abstract: OBJECTIVE
  To assess the efficacy and hemodynamic safety of intravenous lorazepam as an amnestic and anxiolytic agent in patients undergoing critical care procedures.
  
  
  METHODS
  Prospective study.
  
  
  METHODS
  Trauma/intensive care unit and coronary care unit of a 524-bed, tertiary, teaching community hospital.
  
  
  METHODS
  Ten patients undergoing critical care procedures.
  
  
  METHODS
  Intravenous lorazepam was administered at an initial dose of 2 mg, 15 to 20 mins before the critical care procedure (procedures included both invasive and noninvasive techniques) was performed. Anxiety level and memory assessment were evaluated at baseline and at various points following lorazepam administration. Changes in hemodynamic status were evaluated regularly throughout the study.
  
  
  RESULTS
  No significant changes in hemodynamic measurements were observed after administration of intravenous lorazepam. Significant differences were seen in anxiety scores and amnestic effects from preprocedure/pre-lorazepam to post-lorazepam evaluations (all p values were < .03).
  
  
  CONCLUSIONS
  This study confirms the beneficial anxiolytic and amnestic effects of lorazepam in a subgroup of patients undergoing critical care procedures. The study also substantiates the safety of this drug in this patient population.
authors.affiliation: Department of Medicine, Mercy Hospital of Pittsburgh, PA 15219.
authors.forename: S A
authors.initials: SA
authors.lastname: Deppe
authors.forename: M E
authors.initials: ME
authors.lastname: Sipperly
authors.forename: A I
authors.initials: AI
authors.lastname: Sargent
authors.forename: R J
authors.initials: RJ
authors.lastname: Kuwik
authors.forename: D R
authors.initials: DR
authors.lastname: Thompson
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000648:Amnesia, Retrograde / Q000139:chemically induced* / Q000175:diagnosis / Q000503:physiopathology; D001007:Anxiety / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D002405:Catheterization, Central Venous / Q000009:adverse effects* / Q000523:psychology*; D002406:Catheterization, Peripheral / Q000009:adverse effects* / Q000523:psychology*; D016292:Procedural Sedation / Q000379:methods*; D003422:Critical Care; D005260:Female; D006439:Hemodynamics / Q000187:drug effects*; D006801:Humans; D007262:Infusions, Intravenous; D008140:Lorazepam / Q000494:pharmacology / Q000627:therapeutic use*; D008297:Male; D008568:Memory / Q000187:drug effects*; D008875:Middle Aged; D011292:Premedication / Q000379:methods*; D011446:Prospective Studies; D012720:Severity of Illness Index
chemical_list: D008140:Lorazepam